Loading...
Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
PURPOSE: A phase II study was conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)–supplied agent investigational new drug No. 59,699) in patients with persistent or recurrent endometrial cancer who have progressed despite standard therapy. PATIENTS AN...
Na minha lista:
Main Authors: | , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
American Society of Clinical Oncology
2009
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2716935/ https://ncbi.nlm.nih.gov/pubmed/19451430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6995 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|